Face–Name Associative Memory Performance Among Cognitively Healthy Individuals, Individuals With Subjective Memory Complaints, and Patients With a Diagnosis of aMCI

Constantinos Kormas,Elisabeth Kapaki,Ioannis Evdokimidis,Ioannis Zalonis,Constantin Potagas

doi:10.3389/fpsyg.2020.02173

Constantinos Kormas, Elisabeth Kapaki + Show 3 more

Open Access

https://doi.org/10.3389/fpsyg.2020.02173

Copy DOI

Abstract

Face–Name Associative Memory Performance Among Cognitively Healthy Individuals, Individuals With Subjective Memory Complaints, and Patients With a Diagnosis of aMCI

Highlights

Alzheimer’s disease (AD) is a neurodegenerative disease characterized by cognitive and behavioral disturbances with insidious initiation and gradual deterioration that significantly affect patients’ quality of life (Castellani et al, 2010)
Recent studies have proposed that biomarker tests with a higher predictive value among asymptomatic cognitively normal individuals are the measurement of amyloid-β and t-tau or p-tau in cerebrospinal fluid (CSF) and/or the amyloid-β positron emission tomography (PET) imaging (Blennow et al, 2010; Herholz and Ebmeier, 2011; Olsson et al, 2016)
Clinical studies have demonstrated that the decreased CSF Aβ42 (Skoog et al, 2003; Gustafson et al, 2007; Stomrud et al, 2007), the combined high CSF t-Tau or p-Tau and low CSF Aβ42 (Soldan et al, 2016), and the higher CSF t-Tau with PiB-PET retention (Dumurgier et al, 2017) are strongly associated with future cognitive decline among normal older adults

Summary

INTRODUCTION

Alzheimer’s disease (AD) is a neurodegenerative disease characterized by cognitive and behavioral disturbances with insidious initiation and gradual deterioration that significantly affect patients’ quality of life (Castellani et al, 2010). Experimental neuroimaging studies have shown that neuronal activity is reduced during the administration of FNAME to sampled participants, who, they did not show clinical symptoms of AD disease, had shown amyloid depositions (Sperling et al, 2009; Vannini et al, 2012) Another neuroimaging study, using positron emission tomography (PET) investigated the correlation between FNAME performance and amyloid load in cognitively healthy individuals (Rentz et al, 2011). It has been empirically documented that the FNAME test highly sensitively differentiates patients with aMCI from cognitively healthy individuals without producing ceiling effects, as is the case of other memory measures, making it useful for the detection of the early changes that characterize the pre-clinical phases of AD. Possible differentiation in the success rates for delayed recall performance within the SMC group and the aMCI group on two different memory modalities test (verbal and cross verbal–visual) was investigated

Participants

Procedure and Neuropsychological Measures

DISCUSSION

Findings

ETHICS STATEMENT